Hemab Therapeutics Holdings, Inc. (COAG)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
28.50 USD
+0.50
(1.786%)
⇧
(May 29, 2026, 4 p.m.
EDT)
After hours: 29.00 +0.50 (1.754%) ⇧ (May 29, 2026, 5:13 p.m. EDT) |
Hot Take ↕ | May 25, 2026, 3:31 a.m. EDT
The immediate outlook is bearish due to a severe lack of liquidity and a precarious post-IPO structure. Trading volume is less than half of the average, creating a fragile environment where price moves are easily distorted by small capital flows, and the recent price action shows no sustained upward momentum despite a brief spike. The long-term investment case is nonexistent; the company is a biotech startup with negative book value, massive losses, and no earnings history, making it a classic speculative venture rather than a viable long-term holding. Furthermore, there is absolutely no dividend income to offset the high risk of total capital loss. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 1,331,104,128 |
| Forward P/E | -12.26 |
| Website | https://www.hemab.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.17647058 |
| Address1 | 101 Main Street |
| Address2 | Suite 1220 |
| All Time High | 36.61 |
| All Time Low | 23.0 |
| Ask | 29.19 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 160,190 |
| Average Daily Volume3 Month | 438,221 |
| Average Volume | 438,221 |
| Average Volume10Days | 160,190 |
| Bid | 29.05 |
| Bid Size | 4 |
| Book Value | -186.718 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.5 |
| Current Ratio | 18.034 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,778,803,200 |
| Day High | 29.44 |
| Day Low | 27.2894 |
| Display Name | Hemab Therapeutics |
| Earnings Timestamp | 1,779,366,600 |
| Earnings Timestamp End | 1,786,710,600 |
| Earnings Timestamp Start | 1,786,710,600 |
| Ebitda | -69,815,000 |
| Ebitda Margins | 0.0 |
| Eps Current Year | -3.035 |
| Eps Forward | -2.325 |
| Eps Trailing Twelve Months | -10.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.936842 |
| Fifty Day Average Change | 1.563158 |
| Fifty Day Average Change Percent | 0.058030486 |
| Fifty Two Week Change Percent | -17.647058 |
| Fifty Two Week High | 36.61 |
| Fifty Two Week High Change | -8.110001 |
| Fifty Two Week High Change Percent | -0.2215242 |
| Fifty Two Week Low | 23.0 |
| Fifty Two Week Low Change | 5.5 |
| Fifty Two Week Low Change Percent | 0.23913044 |
| Fifty Two Week Range | 23.0 - 36.61 |
| First Trade Date Milliseconds | 1,777,642,200,000 |
| Float Shares | 456,133 |
| Forward Eps | -2.325 |
| Forward P E | -12.258064 |
| Free Cashflow | -39,593,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10781 |
| Held Percent Institutions | 0.59905 |
| Implied Shares Outstanding | 46,705,410 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-05-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts. |
| Long Name | Hemab Therapeutics Holdings, Inc. |
| Market | us_market |
| Market Cap | 1,331,104,128 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1994300807 |
| Net Income To Common | -63,913,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,303,080,939 |
| Number Of Analyst Opinions | 4 |
| Open | 27.7 |
| Operating Cashflow | -61,475,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | (617) 553-3952 |
| Post Market Change | 0.5 |
| Post Market Change Percent | 1.754386 |
| Post Market Price | 29.0 |
| Post Market Time | 1,780,089,219 |
| Previous Close | 28.0 |
| Price Eps Current Year | -9.390445 |
| Price Hint | 2 |
| Price To Book | -0.15263659 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.619 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.5 |
| Regular Market Change Percent | 1.7857144 |
| Regular Market Day High | 29.44 |
| Regular Market Day Low | 27.2894 |
| Regular Market Day Range | 27.2894 - 29.44 |
| Regular Market Open | 27.7 |
| Regular Market Previous Close | 28.0 |
| Regular Market Price | 28.5 |
| Regular Market Time | 1,780,084,801 |
| Regular Market Volume | 122,705 |
| Return On Assets | -0.30114 |
| Return On Equity | -0.46994 |
| Sand P52 Week Change | 0.2794361 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 46,705,410 |
| Shares Percent Shares Out | 0.0162 |
| Shares Short | 758,697 |
| Short Name | Hemab Therapeutics Holdings, In |
| Short Ratio | 1.19 |
| Source Interval | 15 |
| State | MA |
| Symbol | COAG |
| Target High Price | 50.0 |
| Target Low Price | 36.0 |
| Target Mean Price | 41.75 |
| Target Median Price | 40.5 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.936842 |
| Two Hundred Day Average Change | 1.563158 |
| Two Hundred Day Average Change Percent | 0.058030486 |
| Type Disp | Equity |
| Volume | 122,705 |
| Website | https://www.hemab.com |
| Zip | 2,142 |